Mickiddn, of course instead of the expected 17 more idiotic posts today, you could pack up and move on---retire from your obsession of the last 2 years.
2 down, Mckiddn: hurry if you're going to get to 20 insipid, repetitive posts on just this board today.
Excellent, Mckiddn: one down, 19 more vapid, repetitious posts to go for you on this board today. Will you post it in 30 seconds or 1 minute from now? Hurry.
Hanna, you are a chameleon and tumble between extremes of berating the company and Geert, expressing recriminative hopelessness, and jubilative cheerleading.
That now you plea for a donation of slack to be offered the company for fundamential and essential omission in the announcement of a deal, their failure upon clear notice to repair that omission, and, perhaps worst, the failure and refusal of IR to even respond to inquiries that pointed out the omission, requested remedy, or at least explanation by email ( "didn't RXI get ANYTHING in exchange?")--a thoroughly unacceptable, unprofessional, and not shareholder-friendly dereliction--your request for slack is unfathomable.
I think it's shocking that RXI's IR did not respond previously to omissions in their last PR and inquiries about the Thera deal, yet include the (vague) equity position and "potential" for cash milestones and more equity in their Q, K, and PR today. Why wasn't that included in the original PR? Why couldn't they have issued an amended PR to add that info, why couldn't IR respond to inquiries in that regard. Put that together with lack of 10Q audit, and questions arise.
Guess the CFO has been consumed with deal discussion and calculations, as 10q says results are unaudited, contains some approximations, and compresses or omits some footnotes, etc.
Is this going to be remedied soon?
Bio, Thks for posting Edison excerpt. Unless they are using some slight of word, they seem to be stating as fact that RXI has had some degree of partnership inquiry from J&j, Unilever, P&G. Interesting that Edson would know this, but we don't. As they state, "...RXI is exploring options for internal or collaborative development paths having received multiple requests from potential partners. Potential partners include large consumer goods companies such as Unilever, P&G, J&J and Shiseido and commercialization would likely span geographical regions. As guided by management, we anticipate RXI will receive one-time milestones of approx. $2m from each.... "
Hanna, Bio, I don't disagree: the PR was the catalyst, the shorts now have to be more careful and leery of more news that could catalyze both retailing buying and short covering.
Yes, I know you're proud of learning the term "pump n' dimp," but it doesn't apply here at all. There has been no pump ( no concerted campaign touting RXI as a must buy) and no dump ( by those who held shares before the pump). Rather, in RXI we have seen, generally, " short and short some more," Yesterday's sharp increase was largely short covering after some buying based on Griffen news PR, a situation ( Griffin) which contonues today and they will still be hired tomorrow: hence no pump, and no dump by pre-holders.
Short covering yesterday mostly responsible for acute price increase, and after seeing no price increase in opening 30 minutes, the shorts jump back in with both feet, and the algorithmic display continues. Has little to do with the company-- just virtually free money for the mechanized shorts.
Looked like a lot of short covering to me. And I don't agree at all with Bio that Broadfin would wait post-split to sell. I think we saw THAT selling before the split.
Reyes, the "market" isn't really pricing it based on potential of its pipeline, ip valuation etc. The "Market" as we have witnessed it once Tang converted and sold out many months ago, has been pure hft, algorithmic, short-dominated, bear-raiding "artificial " precipitous decline. This stock, absent all of that, could easily be trading for $7.50, post-split, based on potential breakthroughs in dermal and ocular scarring, as well as cosmetic potentials. Yes, it might never be realized, but investors often bet on the reasonable come.